MENU
RLMD
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Relmada Therapeutics (RLMD) Earnings Date & Reports

Relmada Therapeutics Inc is a clinical-stage biotechnology company... Show more

A.I. Advisor
published Earnings

RLMD is expected to report earnings to rise 18.90% to -35 cents per share on March 24

Relmada Therapeutics RLMD Stock Earnings Reports
Q4'25
Est.
$-0.36
Q3'25
Beat
by $0.15
Q2'25
Beat
by $0.10
Q1'25
Missed
by $0.21
Q4'24
Beat
by $0.09
The last earnings report on November 13 showed earnings per share of -30 cents, beating the estimate of -44 cents. With 1.53M shares outstanding, the current market capitalization sits at 313.87M.
View a ticker or compare two or three
RLMD
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. RLMD showed earnings on November 13, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

a clinical-stage biotechnology company, which engages in the development of d-methadone receptor antagonist, which is a chemical entity that addresses areas of high unmet medical need in the treatment of central nervous system diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
2222 Ponce de Leon Boulevard
Phone
+1 786 629-1376
Employees
20
Web
https://www.relmada.com